Two replicate, phase 3 trials (LAVOLTA1 and LAVOLTA2) explored the use of periostin and eosinophilia (≥ 300 cells/μl) as biomarkers of IL-13-driven inflammatory patterns in patients with severe uncontrolled asthma treated with lebrikizumab (37.5 mg or 125 mg s.c. once every 4 weeks for 52 weeks or placebo) (Hanania et al., 2016). This evidence concerns the gene IL13 and Increased total eosinophil count.